Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Status:
Completed
Trial end date:
2015-05-05
Target enrollment:
Participant gender:
Summary
This study is intended to investigate the combination of the combination of dexamethasone
(Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) [ClaPd] in multiple
myeloma patients who have relapsed or refractory disease who have failed prior treatment with
lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be
response rate to treatment. Secondary endpoints will include toxicity of the combination,
time to maximum response, and time to disease progression